Cita APA

Montejano, R., Borobia Pérez, A. M., Carcas Sansuán, A. J., Arribas López, J. R., & Group, P. S. (2022). Tenofovir disoproxil fumarate/emtricitabine and baricitinib for patients at high risk of severe Coronavirus disease 2019: The PANCOVID randomized clinical trial.

Citación estilo Chicago

Montejano, Rocío, Alberto M. Borobia Pérez, Antonio Javier Carcas Sansuán, José Ramón Arribas López, y PANCOVID Study Group. Tenofovir Disoproxil Fumarate/emtricitabine and Baricitinib for Patients At High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. 2022.

Cita MLA

Montejano, Rocío, et al. Tenofovir Disoproxil Fumarate/emtricitabine and Baricitinib for Patients At High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. 2022.